Cargando…

Cerebral infarction in advanced non-small cell lung cancer: a case control study

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) patients often develop thromboembolic events, including cerebral infarction (CI). However, the relationship between advanced NSCLC and CI has not been thoroughly investigated. We examined the association between advanced NSCLC and CI and risk f...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kato, Motoyasu, Shukuya, Takehito, Mori, Keita, Kanemaru, Ryota, Honma, Yuichiro, Nanjo, Yuta, Muraki, Keiko, Shibayama, Rina, Koyama, Ryo, Shimada, Naoko, Takahashi, Fumiyuki, Takahashi, Kazuhisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4785661/ https://www.ncbi.nlm.nih.gov/pubmed/26964872 http://dx.doi.org/10.1186/s12885-016-2233-1

Ejemplares similares

Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
por: Kato, Motoyasu, et al.
Publicado: (2014)

Surfactant protein-D predicts prognosis of interstitial lung disease induced by anticancer agents in advanced lung cancer: a case control study
por: Nakamura, Kota, et al.
Publicado: (2017)

Impact of the generation of EGFR‐TKIs administered as prior therapy on the efficacy of osimertinib in patients with non‐small cell lung cancer harboring EGFR T790M mutation
por: Miyashita, Yosuke, et al.
Publicado: (2020)

Association between the efficacy and immune-related adverse events of pembrolizumab and chemotherapy in non-small cell lung cancer patients: a retrospective study
por: Kurokawa, Kana, et al.
Publicado: (2022)

Survival past five years with advanced, EGFR-mutated or ALK-rearranged non-small cell lung cancer—is there a “tail plateau” in the survival curve of these patients?
por: Shimamura, Shoko Sonobe, et al.
Publicado: (2022)

Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non‐small‐cell lung cancer
por: Kurokawa, Kana, et al.
Publicado: (2022)

Bevacizumab‐induced chronic interstitial pneumonia during maintenance therapy in non‐small cell lung cancer
por: Sekimoto, Yasuhito, et al.
Publicado: (2016)

Phase I study of afatinib plus bevacizumab in patients with advanced non-squamous non-small cell lung cancer harboring EGFR mutations
por: Ko, Ryo, et al.
Publicado: (2021)

Hermansky-Pudlak syndrome-associated pneumothorax with rapid progression of respiratory failure: a case report
por: Kato, Yukari, et al.
Publicado: (2020)

Zinc‐finger E‐box‐binding homeobox 1 (ZEB1) plays a crucial role in the maintenance of lung cancer stem cells resistant to gefitinib
por: Nurwidya, Fariz, et al.
Publicado: (2021)

Dramatic, significant metabolic response to a one‐time pembrolizumab treatment following a relapse of pre‐existing organizing pneumonia in a patient with advanced non‐small cell lung cancer: A case report
por: Kato, Motoyasu, et al.
Publicado: (2021)

Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study
por: Kato, Motoyasu, et al.
Publicado: (2019)

Tocilizumab, a Proposed Therapy for the Cachexia of Interleukin6-Expressing Lung Cancer
por: Ando, Katsutoshi, et al.
Publicado: (2014)

Regional heterogeneity in response of airway epithelial cells to cigarette smoke
por: Baskoro, Hario, et al.
Publicado: (2018)

LSD1/KDM1 isoform LSD1+8a contributes to neural differentiation in small cell lung cancer
por: Jotatsu, Takanobu, et al.
Publicado: (2016)

Successful restart of chemotherapy in a patient with primary mediastinal nonseminomatous germ cell tumor after COVID‐19 infection
por: Tanabe, Yuki, et al.
Publicado: (2022)

Idiopathic dendriform pulmonary ossification diagnosed by bronchoscopic lung cryobiopsy: A case report
por: Sekimoto, Yasuhito, et al.
Publicado: (2021)

Loxoprofen-induced interstitial pneumonia: a case report
por: Kato, Motoyasu, et al.
Publicado: (2016)

TWEAK enhances TGF-β-induced epithelial-mesenchymal transition in human bronchial epithelial cells
por: Itoigawa, Yukinari, et al.
Publicado: (2015)

Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2019)

Author Correction: Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis
por: Kato, Motoyasu, et al.
Publicado: (2020)

Transformation from adenocarcinoma to squamous cell lung carcinoma with MET amplification after lorlatinib resistance: A case report
por: Ueda, Shoko, et al.
Publicado: (2021)

Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor
por: Murakami, Akiko, et al.
Publicado: (2014)

Early Detection of Therapeutic Benefit from PD-1/PD-L1 Blockade in Advanced Lung Cancer by Monitoring Cachexia-Related Circulating Cytokines
por: Xu, Shiting, et al.
Publicado: (2023)

Atezolizumab‐induced fulminant type 1 diabetes mellitus occurring four months after treatment cessation
por: Nishioki, Toshihiko, et al.
Publicado: (2020)

Heterogeneous Outcomes of Immune Checkpoint Inhibitor Rechallenge in Patients With NSCLC: A Systematic Review and Meta-Analysis
por: Xu, Shiting, et al.
Publicado: (2022)

Tranilast Inhibits Pulmonary Fibrosis by Suppressing TGFβ/SMAD2 Pathway
por: Kato, Motoyasu, et al.
Publicado: (2020)

Activation of insulin‐like growth factor‐1 receptor confers acquired resistance to osimertinib in non‐small cell lung cancer with EGFR T790M mutation
por: Hayakawa, Daisuke, et al.
Publicado: (2019)

CALML5 is a novel diagnostic marker for differentiating thymic squamous cell carcinoma from type B3 thymoma
por: Kanamori, Koichiro, et al.
Publicado: (2023)

Gefitinib in the treatment of nonsmall cell lung cancer with activating epidermal growth factor receptor mutation
por: Nurwidya, Fariz, et al.
Publicado: (2016)

Clinical Significance of Tumor Markers for Advanced Thymic Carcinoma: A Retrospective Analysis from the NEJ023 Study
por: Mimori, Tomoyasu, et al.
Publicado: (2022)

Prognostic impact of serum CYFRA 21–1 in patients with advanced lung adenocarcinoma: a retrospective study
por: Ono, Akira, et al.
Publicado: (2013)

Epithelial Mesenchymal Transition in Drug Resistance and Metastasis of Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012)

Molecular Mechanisms Contributing to Resistance to Tyrosine Kinase-Targeted Therapy for Non-Small Cell Lung Cancer
por: Nurwidya, Fariz, et al.
Publicado: (2012)

Epidemiology, risk factors and impact of cachexia on patient outcome: Results from the Japanese Lung Cancer Registry Study
por: Shukuya, Takehito, et al.
Publicado: (2023)

Highly sensitive fusion detection using plasma cell‐free RNA in non‐small‐cell lung cancers
por: Hasegawa, Nobuhiko, et al.
Publicado: (2021)

Hesitant avoidance while walking: an error of social behavior generated by mutual interaction
por: Honma, Motoyasu, et al.
Publicado: (2015)

Progression-free survival at 2 years is a reliable surrogate marker for the 5-year survival rate in patients with locally advanced non-small cell lung cancer treated with chemoradiotherapy
por: Akamatsu, Hiroaki, et al.
Publicado: (2014)

Hochuekkito (TJ-41), a Kampo Formula, Ameliorates Cachexia Induced by Colon 26 Adenocarcinoma in Mice
por: Yae, Suzu, et al.
Publicado: (2012)

Development of diffuse alveolar damage after initiation of Nijutsuto
por: Kato, Motoyasu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_62pn9vim0gga21briscaf3k21a